Request Paper

Abstract
The study is designed to detect and evaluate with molecular screening the Extended Spectrum beta-lactamases (ESβL) producing strains of Escherichia coli from patients urine, and aimed as to finding solutions to the spread of ESβL producing bacteria which is a matter of great concern in treating infections in hospitals in covid-19 era. A total of 250 isolates from urine samples were studied phenotypically with antimicrobial susceptibility testing that was determined by, kirby bauer disk diffusion and double disk diffusion synergy test as recommended by clinical Laboratory Standard Institute (CLSI) The results showed, out of 250 isolates from urine sample , 110 isolates were E coli 30(37%) isolates positive On the antibiotics used the isolates showed (100%) resistance to ampicillin (10ug) and augumentine (30μg); followed by ofloxacin(5ug); cefuroxime(30μg); ciprofloxacin (ug); ceftazidime (30μg) and gentamicine(5ug). The result of ESβL production with double disk diffusion test (DDDT) with ceftazidime and cefotaxime with and without clavulanic acid at a distant of 30mm and a zone clearing difference greater than  5mm showed 30(45%) positive with isolates of E coli. Presence of acquired ESßL-encoding gene by PCR using 16S rRNA region sequencing analysis by standard identity yielded positive. The detection of extended spectrum βeta-lactamase production by Escherichia coli and their confirmation with molecular screening requires adequate infection control with antibiotic management to avoid risks of treatment failures. Keywords: ESßL, Producing strains, E,coli, clinical specimens, ßeta-lactam, antibiotics.